Metabolon Announces Accreditation by College of American Pathologists
RESEARCH TRIANGLE PARK, N.C. (November 28, 2011) — Metabolon, Inc., a diagnostics and services company offering the industry’s leading biochemical profiling technology, announced today that they have received laboratory accreditation from the College of American Pathologists (CAP).
The CAP Laboratory Accreditation Program is the premier globally-recognized program for laboratory accreditation and the only one of its kind that utilizes practicing laboratory professionals as inspectors. Designed to exceed government regulatory compliance standards, the program assists laboratories to achieve the highest levels of excellence to positively impact patient care. CAP accreditation is based on rigorous standards translated into specific clinically recognized laboratory procedures and methods.
Metabolon’s CEO John Ryals said, “This accreditation means that Metabolon has met exceptionally rigorous standards in order to achieve the highest caliber of diagnostic testing quality. Our CAP accredited lab facility will offer tests developed using Metabolon’s proprietary biochemical profiling technology. The first of these new tests will be Quantose IR for the evaluation of insulin resistance.” Insulin resistance is a primary risk factor for the development of Type 2 diabetes and cardiovascular disease.
Metabolon, Inc. has advanced the field of metabolomics by pioneering and patenting the industry’s leading biochemical biomarker discovery and profiling platform. It has developed the technology to quickly identify and measure all of the biochemicals in a biological sample through its proprietary global processing method. Through the generation and interpretation of data, this method provides a precise understanding of disease etiology and drug action, and advances personalized medicine beyond what genomics and other approaches can promise. Metabolon’s expertise is being embraced by a wide range of pharmaceutical, biotechnology, food and agricultural companies. Metabolytics, its biomarker discovery and analysis business, has completed over 320 client studies and processed over 30,000 samples for customers in 2010 alone. Building on its expertise in biochemistry understanding, Metabolon is also developing proprietary diagnostic tests to determine and track disease progression. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske at email@example.com or 919-595-2200.